SHANGHAI, China – May 8, 2026
Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for 9MW5211, enabling the company to initiate clinical studies for the treatment of inflammatory bowel disease (IBD). The milestone positions 9MW5211 as the world’s first clinical-stage drug candidate for its target, highlighting Mabwell’s growing presence in the global autoimmune disease therapeutics market and reinforcing international interest in next-generation immune-targeting biologics.
The company also confirmed that clinical trial applications for multiple indications, including IBD and multiple sclerosis (MS), have already been accepted for review by China’s National Medical Products Administration (NMPA). The regulatory progress in both the United States and China reflects accelerating development momentum for the novel antibody platform as competition intensifies in autoimmune and inflammatory disease treatment innovation.
9MW5211 Targets Pathogenic Immune Cells in Autoimmune Disease
9MW5211 is a highly specific and depleting antibody independently developed by Mabwell to precisely target the pathological immune mechanisms responsible for autoimmune disorders. According to the company, the therapy selectively recognizes and eliminates abnormal immune cells that drive inflammation and tissue damage in chronic autoimmune diseases.
Mabwell stated that the target molecule addressed by 9MW5211 is specifically expressed on activated pathogenic immune cells, making it a critical biological marker for disease progression. By selectively depleting these harmful cells, the antibody aims to interrupt inflammatory immune cascades while minimizing non-specific immune suppression. This approach could potentially improve both therapeutic efficacy and long-term safety compared with broader immunosuppressive therapies currently used in autoimmune disease management.
Advertisement
The company noted that extensive molecular engineering optimization has significantly enhanced the antibody’s target selectivity and binding precision. Preclinical studies demonstrated that 9MW5211 achieved efficient depletion of pathogenic immune cells while reducing the risk of off-target activity, supporting the potential for deeper disease remission and longer dosing intervals. Mabwell believes these characteristics may improve patient adherence and quality of life by reducing treatment frequency and lowering treatment burden.
Preclinical Data Supports Expansion Into Multiple Indications
Preclinical research conducted by Mabwell showed strong therapeutic activity for 9MW5211 across several mouse models of autoimmune disease, suggesting broad clinical application potential beyond inflammatory bowel disease. Safety evaluations in cynomolgus monkey models also demonstrated a favorable safety profile, supporting advancement into human clinical studies.
The company indicated that additional clinical trial applications targeting other autoimmune indications are actively progressing. Analysts view the program as strategically important given the growing global prevalence of autoimmune diseases and rising demand for targeted biologic therapies capable of delivering improved efficacy with reduced systemic toxicity.
Inflammatory bowel disease, which includes Crohn’s disease and ulcerative colitis, remains one of the fastest-growing chronic immune disorders worldwide. Mabwell cited epidemiological data showing global IBD cases increased from 5.9 million in 2019 to 7 million in 2023, with projections reaching approximately 11.5 million patients by 2032. The continued rise in disease burden is driving significant investment in novel immunology and biologic drug development.
Multiple Sclerosis Expansion Broadens Commercial Opportunity
In addition to IBD, Mabwell is also targeting multiple sclerosis (MS), a chronic autoimmune disease affecting the central nervous system. MS causes inflammatory damage to the protective myelin sheath surrounding nerves in the brain and spinal cord, leading to progressive neurological impairment.
Global MS prevalence has continued increasing steadily, with patient numbers rising from 2.8 million cases in 2020 to approximately 3 million in 2024. Industry projections estimate global MS cases could exceed 3.5 million by 2035, creating substantial long-term demand for innovative immune-targeted therapies.
The FDA clearance for 9MW5211 marks a major milestone for Mabwell as it advances development of first-in-class biologics targeting unmet needs in autoimmune disease treatment. As competition in immunology therapeutics continues expanding, the company’s dual-track regulatory progress in both the United States and China positions it as an emerging player in the rapidly growing global autoimmune biologics market.
Source: Mabwell press release
